School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield HD1 3DH, UK.
J Microencapsul. 2011;28(8):689-708. doi: 10.3109/02652048.2011.590613. Epub 2011 Jul 4.
Many strategies have been proposed to explore the possibility of exploiting gastroretention for drug delivery. Such systems would be useful for local delivery, for drugs that are poorly soluble at higher pH or primarily absorbed from the proximal small intestine. Generally, the requirements of such strategies are that the vehicle maintains controlled drug release and exhibits prolonged residence time in the stomach. Despite widespread reporting of technologies, many have an inherent drawback of variability in transit times. Microparticulate systems, capable of distributing widely through the gastrointestinal tract, can potentially minimise this variation. While being retained in the stomach, the drug content is released slowly at a desired rate, resulting in reduced fluctuations in drug levels. This review summarises the promising role of microencapsulation in this field, exploring both floating and mucoadhesive microparticles and their application in the treatment of Helicobacter pylori, highlighting the clinical potential of eradication of this widespread infection.
许多策略被提出以探索利用胃滞留来进行药物传递的可能性。对于在较高 pH 值下溶解度差或主要从小肠近端吸收的药物,此类系统将非常有用。一般来说,这些策略的要求是载体保持药物的控制释放并在胃中表现出延长的停留时间。尽管有广泛报道的技术,但许多技术都存在一个固有的缺点,即转运时间存在变化。能够广泛分布在胃肠道中的微粒系统可以潜在地最小化这种变化。在被滞留在胃中时,药物以期望的速率缓慢释放,从而减少药物水平的波动。本文综述了微胶囊化在这一领域的有前途的作用,探索了漂浮和粘膜粘附微粒及其在治疗幽门螺杆菌中的应用,突出了根除这种广泛感染的临床潜力。